English हिन्दी
Connect with us

India News

SEARCH FOR COVID 19 VACCINE CONTINES.

Moderna Inc, which is one of the frontrunners in the global hunt for a vaccine development surpassed a crucial stage of the clinical trials. The pharmaceutical giant, which is set to conduct stage-3 trials of its novel mRNA-1273 vaccine in July has said that preliminary studies suggest that one dose of the vaccine may be able to nip the infection and may not pose any serious health adversaries.

Published

on

NINTCHDBPICT000576366845

Moderna Inc, which is one of the frontrunners in the global hunt for a vaccine development surpassed a crucial stage of the clinical trials. The pharmaceutical giant, which is set to conduct stage-3 trials of its novel mRNA-1273 vaccine in July has said that preliminary studies suggest that one dose of the vaccine may be able to nip the infection and may not pose any serious health adversaries. A series of studies conducted on mice found that the vaccine may effectively work garner protection against COVID-19.

The vaccine, which is currently in its second phase of testing is likely to proceed ahead with the third phase of clinical trials, where it plans to involve about 30,000 participants between the ages of 18-55 and those who are at high risk for COVID-19. If all goes well, the company has promised to produce over 100 million doses of its innovative vaccine before the year ends.

In a more promising news coming out of India, a Delhi-based biotechnology company, Panacea Biotec Limited signed a partnership with a US-based pharma company, Refana Inc to develop, manufacture and distribute an experimental COVID-19 vaccine which is currently in the works.

The vaccine prototype, which will make use of an inactivated virus strain has shown effective results in the pre-clinical trials conducted in the US. Toxicology studies and animal trials will be conducted in labs across Delhi and Punjab, following which, the company aims to proceed to human trials in the month of October. Apart from Panacea, there are seven other Indian companies in the league to find a vaccine for COVID-19.

Out of the five vaccine candidates being produced in China, Beijing-based Sinovac Biotech Ltd, which is producing a novel vaccine called CoroVac has said that the vaccine has shown largely positive results on 90% of people being tested in the clinical trials.

The pharma giant went on to say that the vaccine prototype was administered to patients for a 14-day period, following which, more than 90% of people went on to develop neutralizing antibodies after injection.

A vaccine being jointly developed by Oxford University and British-Swedish pharma company AstraZeneca have also been given approvals to conduct stage-3 trials in the country, which is now one of the worst affected nations by the pandemic.

American firm, Johnson and Johnson who is also amongst the 110 groups in contention of vaccine development announced that it was fast-tracking human clinical trials for its innovative recombinant vaccine, which was to be earlier held in the month of September. The trials, which will now be held in July were decided after pre-clinical trials and studies showed promising results.

According to reports, the first stage of trials will involve 1035 healthy participants aged between 18 and 55 based out of the US and Belgium. The company has also sought permission from regulatory boards to start large scale human trials ahead of schedule.

Bollywood news

Hrithik Roshan’s Krrish 4 in trouble? Siddharth Anand exits, Rakesh Roshan steps back from direction

Krrish 4 faces another delay as Siddharth Anand exits and Rakesh Roshan steps back from direction. Budget concerns continue to stall the superhero project.

Published

on

Krrish 4, Hrithik Roshan, Bollywood superhero movie, Siddharth Anand, Rakesh Roshan, Krrish franchise, Bollywood film delays, Krrish 4 budget

The much-anticipated Bollywood superhero film Krrish 4, starring Hrithik Roshan, has hit another roadblock as director Siddharth Anand and his banner Marflix have exited the project. Reports indicate that the film’s budget, reportedly touching ₹700 crore, has made it difficult for production houses to move forward with the project.

Adding to the uncertainty, Rakesh Roshan, who directed the previous installments of the Krrish franchise, has decided to step away from directing the film, choosing to “pass on the baton” to a new director.

Production struggles continue

Krrish 4 has faced multiple delays over the years, and with the exit of Siddharth Anand, the situation has become even more complicated. Hrithik Roshan, who had wanted Anand to direct, is now left looking for a new team to take the project forward.

Although there are reports suggesting that the film’s ₹700 crore budget is the reason for the hurdles, another source has denied these claims, stating that the “astronomical figures doing the rounds are completely untrue.”

New production plans in motion

While Marflix will no longer be part of the film, FilmKraft, the production house owned by the Roshan family, is reportedly looking for a new studio to back the film. With no director or confirmed production house in place, it remains to be seen how and when the film will move forward.

For now, Krrish 4 remains in limbo, with fans eagerly waiting for an official update on its future.

Continue Reading

Cricket news

IML final: West Indies Masters get bigger prize money despite finishing as runners-up, check prize money

India Masters clinched the IML 2025 title, winning ₹1 crore in prize money, while West Indies Masters secured ₹5 crore for finishing runners-up.

Published

on

IML 2025, India Masters, West Indies Masters, Sachin Tendulkar, Brian Lara, Ambati Rayudu, Shahbaz Nadeem, cricket prize money, IML final 2025

Sachin Tendulkar’s India Masters emerged victorious in the inaugural International Masters League (IML), defeating Brian Lara’s West Indies Masters by six wickets in the final. The match, played with intense competition despite featuring retired cricketers, saw India dominate from the start, thanks to a stellar bowling performance by Shahbaz Nadeem and a match-winning knock from Ambati Rayudu.

Prize money breakdown

The India Masters, featuring cricket legends like Yuvraj Singh, Yusuf Pathan, and Irfan Pathan, were awarded a cash prize of ₹1 crore for their triumph. Surprisingly, the West Indies Masters, despite finishing as runners-up, took home a higher prize amount of ₹5 crore.

Ambati Rayudu Shines in the Final

Ambati Rayudu played a crucial role in India’s victory, scoring 74 runs off 50 balls, earning him the Player of the Match award along with a cash prize of ₹50,000.

Full List of Award Winners

Match Awards

Player of the Match: Ambati Rayudu (74 runs off 50 balls) – Rs 50,000

Masterstroke of the Match: Ambati Rayudu (9 fours) – Rs 50,000

Most Sixes in the Match: Ambati Rayudu (3 sixes) – Rs 50,000

Gamechanger of the Match: Shahbaz Nadeem (2/12 in 4 overs)

Most Economical Bowler: Shahbaz Nadeem (economy rate of 3.00)

Season Awards

Most Fours in the Season: Kumar Sangakkara – 38 fours (Rs 5 lakh)

Most Sixes in the Season: Shane Watson – 25 sixes (Rs 5 lakh)

The tournament saw heated moments, including a verbal altercation between Yuvraj Singh and Tino Best, proving that even legends still bring passion and intensity to the game.

Continue Reading

Bollywood news

Kangana Ranaut’s Emergency tops Netflix, sparks debate over Oscars

Kangana Ranaut’s ‘Emergency’ is the #1 trending movie on Netflix. She calls the Oscars “silly,” stating that America wouldn’t acknowledge the film’s political message.

Published

on

Kangana Ranaut, Emergency movie, Emergency on Netflix, Netflix India trending, Kangana Oscars comment, Bollywood news, Sanjay Gupta on Emergency, Indira Gandhi movie

Kangana Ranaut’s latest film, Emergency, has taken the top spot on Netflix India, making it the #1 trending movie on the platform. The film, which portrays the events of the 1975 Emergency in India with Ranaut playing former Prime Minister Indira Gandhi, has garnered widespread praise.

However, when a social media user suggested that the film should be India’s entry for the Oscars, Ranaut had a bold response, dismissing the Academy Awards as “silly.”

Kangana Ranaut’s take on the Oscars

A fan on Twitter wrote, “#EmergencyOnNetflix should go for the Oscars from India. Kangana, what a film.” In response, Ranaut reposted the tweet, stating:

“But America wouldn’t like to acknowledge its real face, how they bully, suppress, and arm-twist developing nations. It’s been exposed in #Emergency. They can keep their silly Oscar. We have National Awards.”

Her remarks come amid growing recognition for the film, which she directed, produced, and starred in.

Filmmaker Sanjay Gupta praises ‘Emergency’

Despite initial skepticism, filmmaker Sanjay Gupta was highly impressed by the film. Sharing his thoughts, he tweeted:

“Today I watched EMERGENCY by @KanganaTeam. Very frankly I wasn’t planning to as I had prejudged it. I am so glad that I was wrong. What a fantastic film by Kangana—both performance & direction. Top Notch & World Class.”

Ranaut acknowledged his praise, calling for the industry to shed its “hate and prejudices” and judge films based on merit rather than preconceived notions.

Ranaut on her performance in ‘Emergency’

Many fans have lauded her acting in the film, with some calling it her best performance to date, surpassing her acclaimed roles in Queen, Tanu Weds Manu Returns, Fashion, and Thalaivi.

In response, Ranaut said:

“People are calling my acting in #Emergency amazing and my best ever. Could I surpass Queen, TWM2, Fashion, Thalaivi? Watch #Emergency and find out.”

Emergency tops Netflix charts

Released on March 15, 2025, Emergency has climbed to the #1 spot on Netflix India’s movies list, ahead of Ajay Devgn’s Azaad and Naga Chaitanya-Sai Pallavi’s Thandel.

Apart from Kangana Ranaut, the film features a stellar cast including Anupam Kher, Shreyas Talpade, Vishak Nair, Milind Soman, and the late Satish Kaushik. Produced by Zee Studios and Manikarnika Films, the film offers a dramatic retelling of the 21-month Emergency period imposed in 1975.

Continue Reading

Trending

© Copyright 2022 APNLIVE.com